Related by context. All words. (Click for frequent words.) 85 products MKC# PP 82 MKC# 81 MKC# MKC# PP 77 oncolytic virus therapies 77 LymphoStat B belimumab 77 SinuNase TM 77 Initiates Phase II 77 including eniluracil ADH 77 novel VDA molecule 77 pralatrexate injection folate analogue 76 MCSP respectively 76 orally administered inhibitor 76 Personalized Immunotherapy 76 CYT# potent vascular disrupting 76 Aflibercept 76 Solazed TM 76 VEGFR2 inhibitor 75 investigational monoclonal antibody 75 Completes Patient Enrollment 75 GVAX ® 75 XL# anticancer compounds 75 lintuzumab SGN 75 AFRESA ® 75 phase III isavuconazole 75 AAG geldanamycin analog 75 Phase 2b Clinical Trial 75 AFREZZA TM 75 dasatinib Sprycel ® 75 oral proteasome inhibitor 75 ALN HPN 75 Initiates Enrollment 75 antibody MAb 74 AFREZZA ™ 74 includes investigational compounds 74 TBC# 74 oral prodrug 74 Xcytrin R 74 agonistic human 74 TKB# 74 non nucleoside inhibitor 74 Crofelemer budesonide foam 74 delta opioid receptor 74 ALN PCS 74 Commences Phase 74 virus HCV protease inhibitor 74 includes TOLAMBA TM 74 kidney urologic 74 hypoxia activated prodrug 74 Meets Primary Endpoint 74 Achieves Primary Endpoint 74 targeted radiotherapeutic 74 oral Janus kinase 74 phenylalanine ammonia lyase 73 myelofibrosis polycythemia vera 73 Randomized Phase 73 evaluating picoplatin 73 investigational compounds 73 Telik logo TELINTRA 73 Begins Dosing 73 Trial Evaluating 73 2 methoxyestradiol 73 Combination REOLYSIN R 73 acetylgalactosamine 6 73 Tesetaxel 73 Successfully Completes Phase 73 IMA# 73 alfimeprase direct 73 sodium thiosulfate STS 73 TELINTRA R 73 MAGE A3 ASCI 73 oral nucleoside analogue 73 ADP receptor antagonist 73 humanized therapeutic 73 Quinamed R 73 FOLOTYN ® 73 R Saizen R 73 Initiate Phase 73 Daclizumab 73 investigational humanized monoclonal antibody 73 Pruvel TM 73 Trastuzumab DM1 73 muscarinic receptor agonist 73 telomerase therapeutic 73 Ovitrelle R Serostim 73 LymphoStat B TM 73 oral ghrelin agonist 73 antiangiogenesis therapies 73 Syncria albiglutide 73 PEG PAL PEGylated recombinant 73 induced macular edema 73 SinuNase ™ 73 PEGylated Fab fragment 73 SAR# [002] 73 Romidepsin 73 BiovaxID TM 73 Pivotal Phase III 73 SPRYCEL ® 73 IgG1 monoclonal antibody 73 NU# direct 73 huC# DM4 73 Cetrorelix 73 Archexin 73 neuropathic pain metabolic diseases 73 CD# CEA 73 Pivotal Phase 72 candidates Azedra TM 72 essential thrombocythemia ET 72 dependent kinase inhibitor 72 erlotinib Tarceva ® 72 Vicriviroc 72 5 fluorouracil leucovorin 72 IMiDs R 72 6 sulfatase 72 include GALNS N 72 Peginterferon alfa 2b 72 Panzem R 72 Initiates Clinical Trial 72 humanized interleukin 6 72 sapacitabine CYC# 72 RELOVAIR ™ 72 Files IND 72 candidate AQ4N 72 docetaxel Taxotere R 72 Elagolix 72 Zemiva TM 72 Dementia Related Psychosis 72 TRANSDUR ® 72 albiglutide 72 acyclovir Lauriad R 72 INSPIRE Trial Phase III 72 CDK cyclin dependent 72 formerly LymphoStat B 72 retinal vein occlusion induced 72 TRIOLEX ™ 72 Initiates Phase III 72 receptor tyrosine kinase inhibitor 72 Testosterone MDTS ® 72 Vidaza R 72 systemic juvenile idiopathic 72 Hsp# Inhibitor 72 catheter occlusion 72 DEB# 72 oral picoplatin 72 serine protease inhibitor CU# 72 Initiates Clinical 72 HyperAcute 72 Testosterone MDTS R 72 Rigel R# 72 AFREZZA ® 72 IMPDH inhibitor 72 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 72 Qnexa TM 72 Hormone Refractory Prostate Cancer 72 IMiDs ® 71 HGS ETR1 mapatumumab 71 Bayer HealthCare Onyx Pharmaceuticals 71 personalized dendritic cell 71 psoriasis rheumatoid arthritis 71 metaglidasen 71 MT#/MEDI-# 71 Tezampanel 71 pan HDAC inhibitor 71 relapsed leukemia 71 drug pipeline TAFA# 71 PI3K/Akt pathway inhibitor 71 BENLYSTA ® 71 IL# PE#QQR 71 triggers apoptosis programmed 71 GW# [003] 71 Empatic TM 71 recombinant PSMA vaccine 71 BENLYSTA TM 71 Novel Oral 71 Atripla combines 71 Phase #b/#a clinical 71 sodium glucose cotransporter 71 PDX pralatrexate 71 accumulate preferentially 71 PRN FDA Approves 71 mecarbil 71 Ridaforolimus 71 liposomal formulation 71 Initiates Phase 71 Completes Enrollment 71 Mg Usa 71 imatinib Gleevec ® 71 candidate XP# 71 Oral Calcitonin 71 diarrhea predominant irritable 71 Vitrasert R 71 Luveris R Ovidrel R 71 Amigal TM 71 Safinamide 71 relapsed MM 71 2 inhibitor CYT# 71 CYP#A# CYP#D# 71 Omacetaxine 71 vinorelbine tartrate 71 pharmacogenomic translational research 71 pentadentate logo R 71 delivers fluocinolone acetonide FA 71 PANVAC VF 71 Vaccine Adjuvant 71 recurrent metastatic ovarian cancer 71 selective phosphodiesterase 71 modified glutathione analog 71 non porcine pancreatic 71 CTAP# Capsules 71 P#X# antagonist 71 Onalta ™ 71 PNP inhibitor 71 human IgG1 monoclonal 71 treat chronic sinusitis 71 Budesonide foam crofelemer 71 Factor Receptor 71 Ceflatonin R 71 RANK Ligand inhibitor 71 pan histone deacetylase 71 Presents Preclinical 71 GVAX R 71 Saxagliptin 71 cetuximab Erbitux R 71 albiglutide currently 71 HCV polymerase inhibitors 71 refractory gout 71 Phase IIb Trial 71 mertansine 71 HepeX B TM 71 leading oral taxane 71 AKT inhibitor 71 anti botulism antibody 71 Aurexis R 71 diarrhea fatigue asthenia 71 Liprotamase 71 Receives Orphan Drug Designation 71 Phase 2b Trial 71 candidates Azedra 71 Second Pivotal Phase 70 itraconazole Sporanox 70 refractory chronic lymphocytic 70 receptor inhibiting monoclonal 70 Phase 2a Clinical Trial 70 Empatic ™ 70 acetonide FA 70 Prodarsan R 70 sublingual tablet formulation 70 Biogen Genentech 70 brand ciclesonide HFA 70 selective immunoproteasome inhibitor 70 Ribavirin causes 70 Zemiva ™ 70 Elotuzumab 70 beta 1a 70 ionotropic glutamate receptor antagonists 70 Shigatoxin producing E. coli 70 lexidronam injection 70 Panzem R NCD 70 Dose Ranging Study 70 investigational antiplatelet agent 70 Epratuzumab 70 tiapamil 70 gastro intestinal inflammation 70 Sapacitabine 70 protein tyrosine phosphatase 1B 70 demonstrated antitumor activity 70 Janus kinase 70 alvespimycin 70 product platforms AZX# 70 fibrosis IPF 70 clinical trials Archexin 70 Presents Preclinical Data 70 YONDELIS 70 proteasome inhibitor 70 Ostabolin C TM 70 R sorafenib tablets 70 sunitinib Sutent ® 70 selective kinase inhibitor 70 R roscovitine CDK cyclin 70 NS5b 70 PDE4 inhibitor 70 ATRA IV 70 XL# XL# 70 Lenocta TM 70 TELINTRA 70 myocardial infarction ventricular fibrillation 70 toenail onychomycosis 70 Initiate Clinical Trial 70 arsenic trioxide injection 70 topical gel formulation 70 cutaneous T 70 mGluR5 negative 70 Phase III Pivotal 70 antibody MT# 70 mGluR5 NAM 70 Solazed ™ 70 personalized cellular immunotherapy 70 HCV NS5B polymerase 70 Luramist TM 70 midstage clinical 70 development peramivir neuraminidase 70 novel therapeutic antibodies 70 MAb therapy 70 Submits Biologics License Application 70 platforms GVAX 70 Phase Ib IIa 70 TRACON Pharmaceuticals 70 occlusion PAO 70 multi kinase inhibitor 70 candidate deforolimus 70 cardiac myosin activator omecamtiv 70 using VIAdel TM 70 Ecallantide 70 Initiated Phase 70 IAP inhibitor 70 REGN# 70 Custirsen 70 NicVAX TM 70 THR beta agonist 70 oral dihydropyrimidine dehydrogenase DPD 70 QNEXA ® 70 Factor VIIa 70 vapreotide acetate 70 anti CD3 monoclonal 70 ALN VSP Phase 70 molecular imaging radiopharmaceutical 70 peptidic compound 70 Immunotherapeutic 70 selective modulator 70 Romiplostim 70 adecatumumab MT# 70 DP VPA 70 Alfacell proprietary ribonuclease 70 myelodysplastic myeloproliferative diseases 70 product candidate Lpathomab 70 dimebon latrepirdine 70 Investigational Oral 70 interferon gamma 1b 70 Hemispherx flagship products 70 monoclonal antibody conjugated 70 tramiprosate Alzhemed TM 70 elotuzumab 70 HCD# [002] 70 Amgen Neulasta R 70 Presents Positive 70 TRAIL receptor antibodies 70 Pimavanserin 70 systemic anaplastic large 70 non nucleoside HCV 70 TransVax 70 anti PlGF 70 Frozen Shoulder syndrome Adhesive 70 SPL# Gel vaginal microbicide 70 Drug Candidate 70 monoclonal antibody IgG1 Mab 70 highly purified pasteurized 70 ASONEP TM 70 Exherin TM 70 First Patient Dosed 70 trastuzumab Herceptin R 70 non peptidic protease 70 epothilones 70 Golimumab 70 Ozarelix 70 Vidaza ® 70 adalimumab Humira 70 Gentamicin Surgical Implant 70 Tumour Vascular Disrupting Agent 70 ALS #-# 70 particularly SANCTURA XR 70 severe hypercholesterolemia 70 humanised monoclonal antibody 70 SUPPRELIN R LA 70 gastrin analogue TT 70 AEG# 70 Epothilone D 70 oropharyngeal candidiasis OPC 70 oritavancin semi 70 R MSCRAMM 70 Anidulafungin 69 NASH Huntington 69 Provectus Pharmaceuticals specializes 69 Syncria R 69 inflammatory PDE 69 dasatinib Sprycel 69 developing Bicifadine serotonin 69 Sudhir Agrawal D.Phil 69 Allovectin 7 69 TNF Tumor Necrosis Factor 69 PORxin TM platforms 69 Metastatic Melanoma 69 Trofex TM 69 Alocrest 69 Zorbtive TM 69 Commence Phase 69 hypereosinophilic syndrome 69 familial amyloidotic polyneuropathy FAP 69 anaphylactic reactions bronchospasm 69 R lenalidomide 69 Dapagliflozin 69 RhuDex TM 69 interferon alpha IFN 69 TNFerade ™ 69 overactive bladder AA# 69 nilotinib Tasigna ® 69 EOquin TM phase 69 multicenter Phase III 69 cromolyn sodium 69 induced mucositis 69 evaluating tivozanib 69 Letairis ambrisentan 69 Phase IIb Clinical Trial 69 candidate CRLX# 69 inflammatory autoimmune diseases 69 targeted immunotherapies 69 phase IIb clinical 69 4SC AG ISIN DE# 69 Neuvenge 69 HCV RNA polymerase 69 clinical trials Archexin ® 69 Friedreich Ataxia FRDA 69 leukemia AML 69 Ophena TM 69 rheumatoid arthritis psoriatic arthritis 69 Cannabinor 69 AN# topical anti 69 acute peripheral arterial 69 ® bortezomib 69 reslizumab 69 Acute Exacerbations 69 docetaxel Taxotere ® 69 investigational oral inhibitor 69 Tibotec Therapeutics division 69 non alcoholic steatohepatitis 69 Mylan Receives Approval 69 TRIOLEX HE# APOPTONE HE# 69 volociximab 69 Silodosin 69 INS# [001] 69 methylnaltrexone bromide 69 next generation URAT1 69 oxybutynin ATD TM 69 brivanib 69 OAB overactive bladder 69 Temsirolimus 69 Phase 1b clinical trials 69 OvaRex ® MAb 69 include Phenoptin TM 69 Bezielle 69 BCG refractory carcinoma 69 investigational protease inhibitor 69 reversible inhibitor 69 TransVax ™ 69 Pazopanib 69 aldehyde dehydrogenase ALDH2 deficiency 69 LUNESTA ® 69 Evoltra ® 69 Iluvien ® 69 Proellex TM 69 Bazedoxifene 69 Orally administered 69 sapropterin dihydrochloride Phase 69 Veronate R 69 targeted antifolate 69 Inhalation Powder 69 Complicated Skin 69 novel emulsion formulation 69 MOVIPREP R 69 CCR9 antagonist 69 Neulasta R 69 either acutely decompensated 69 PEGylated interferon beta 1a 69 include PLX IBD 69 prokinetic agent 69 seliciclib CYC# 69 clinical trials dacetuzumab SGN 69 Clolar ® 69 Luteinizing Hormone Releasing Hormone 69 ALN TTR 69 metastatic carcinoid 69 histone deacetylase HDAC inhibitor 69 Talabostat 69 targeting Inflammatory Bowel 69 PEGylated anti 69 Cloretazine ® 69 IMC #B 69 REMOXY POSIDUR ELADUR 69 Epidermal Growth Factor Receptor 69 triciribine phosphate monohydrate 69 castrate resistant prostate cancer 69 Acetavance TM intravenous acetaminophen 69 OMP #R# 69 HEPLISAV TM hepatitis B 69 Xanafide 69 Patients Treated With 69 OvaRex R 69 Transdermal Patch 69 Tofacitinib 69 Nicotine Conjugate Vaccine 69 compound INCB# 69 Therapeutic Competitors Companies 69 Enzastaurin 69 Completes Dosing 69 R#/MEM # 69 Oral Fingolimod 69 PGL# 69 cMET 69 5 HT2A inverse 69 lead molecular radiotherapeutic 69 BiTE R 69 Xyfid TM 69 HCV polymerase 69 vaginal candidiasis 69 markets HP Acthar 69 Muraglitazar 69 Monopril 69 rusalatide acetate 69 polysaccharide polymer 69 delivery polymer matrix 69 Kit CD# positive 69 Sphingomab TM 69 resistant hormone refractory 69 Fx #A 69 rALLy clinical trial 69 Aganocide 69 ASONEP ™ 69 DepoCyt ® Abelcet ® 69 Files Investigational 69 Tarceva TM 69 Pafuramidine 69 attach auristatin 69 NS#/#A protease 69 chronic eosinophilic leukemia 69 hematological cancers notably 69 intranasal formulation 69 Maribavir 69 Pharma Merck Serono 69 metastatic colorectal 68 NS5B polymerase 68 alpha folate receptor 68 Recombinant Human 68 JZP 68 CysDisplay R 68 small molecule tyrosine 68 polycythemia vera essential thrombocythemia 68 Diamyd ® 68 generation purine nucleoside 68 novel antimitotic agent 68 5 HT2A serotonin 68 non splenectomized 68 Submits Response 68 Piperacillin 68 Granted Orphan Drug 68 MPS IVA 68 Obatoclax 68 include Alferon N 68 COPEGUS R 68 dihydrochloride Tablets 68 Randomized Phase II 68 5 HT4 68 CYT# vascular disrupting 68 Collaborators Present 68 Multiple Sclerosis Rheumatoid Arthritis 68 TRO# 68 nephropathic cystinosis 68 PMX # heptagonist 68 Vascular Disrupting Agent 68 orally inhaled migraine 68 Cytogen marketed 68 vinca alkaloid 68 bone marrow reticulin deposition 68 colorectal bladder 68 Demonstrates Positive 68 RhuDex R 68 ELADUR ™ 68 neuronal nicotinic receptor NNR 68 Onalta TM 68 Investigational Compound 68 apricitabine ATC 68 Belimumab 68 Pooled Analysis 68 Albuferon TM 68 Ofatumumab 68 Zemiva TM Trofex TM 68 Eculizumab 68 RON Notch 68 Cerebril TM 68 herpetic keratitis 68 Initiates Phase 2b 68 CEL SCI Phase III 68 sarcoma melanoma 68 Previously Treated 68 forodesine 68 thrombin component 68 evaluating bafetinib 68 RhuDex ® 68 Fludara ® 68 Dasatinib 68 PDE# 68 Systemic lupus erythematosus SLE 68 novel immunotherapies 68 idiopathic thrombocytopenic purpura ITP 68 secretory phospholipase A2 68 topical antifungal product 68 ketolide antibiotic 68 Methylnaltrexone 68 Staphylococcus aureus Immune Globulin 68 nucleoside analog 68 Tramiprosate ALZHEMED TM 68 diabetes irritable bowel 68 budesonide foam 68 solid tumors ZYBRESTAT 68 5 HT3 antagonist 68 ragweed allergy immunotherapeutic 68 Pivotal Study 68 interferon beta 1a infertility 68 ovarian cancer chronic hepatitis 68 Combivir Kivexa 68 generation URAT1 inhibitor 68 E1 INT TM 68 Fovea Pharmaceuticals subsidiary 68 peptibody 68 trastuzumab DM1 68 CTAP# Injection 68 GRNVAC1 68 Lenocta 68 Phase IIa Clinical Trial 68 IAP inhibitors 68 trastuzumab DM1 T DM1 68 vaccines oncolytic virus 68 CML CP 68 HGS ETR2 68 memantine HCl 68 TTR amyloidosis 68 hepatitis C lupus 68 soluble tumor necrosis 68 Unit Dose Budesonide 68 RTP #i 68 clinical trials SGN 68 M2 subunit 68 topically applied SEPA 68 biodefense pathogens 68 Pancreas Cancer Vaccine 68 Bosutinib 68 CTAP# 68 KRYSTEXXA TM pegloticase 68 candidate REP# 68 rxRNA 68 HIV treatments Reyataz 68 hyaluronidase enzyme 68 Investigational Treatment 68 Granulocyte Colony Stimulating Factor 68 XOMA 3AB biodefense 68 Severe Sepsis 68 HuCAL PLATINUM ® CysDisplay 68 HIV AIDS neuropathic pain 68 Amgen Neulasta ® 68 ADCC enhanced 68 PEG irinotecan 68 Fabry Disease 68 KSP inhibitor 68 ALTROPANE R 68 pneumocystis pneumonia PCP 68 Myelofibrosis 68 FUSILEV ® 68 compound PMX # 68 EXPLORE Xa 68 TransVax TM 68 peripherally acting 68 FDA APPROVES 68 OTC BB PVCT 68 non constipating irritable 68 include Altastaph TM 68 PMX # antibiotic 68 AVE# 68 treat refractory angina 68 generation Hsp# inhibitor 68 Zalypsis 68 unique alkylating agent 68 Naive Patients 68 nanofiltered plasma derived 68 BCR ABL inhibitors 68 CD4 monoclonal antibody 68 Patient Enrollment 68 LHRH receptor positive 68 rash pruritus nausea 68 includes VIAtab TM 68 Clinical Trial Results 68 Pegloticase 68 gefitinib Iressa 68 polyglutamate 68 prescribed proton pump 68 RGB # 68 Mg Uk 68 thiazolides 68 synthetic lipoglycopeptide antibiotic 68 TLR9 agonist 68 Valopicitabine 68 PROSTASCINT R 68 canagliflozin 68 diaper dermatitis complicated 68 MEK Inhibitor 68 K ras mutations 68 Albuferon albinterferon alfa 2b 68 aripiprazole Abilify 68 Aurora Kinase 68 Reports Preclinical Data 68 Azacitidine 68 OncoVex 68 progressive metastatic prostate 68 Aplidin R 68 Matrix Phase 2b 68 GALNS N acetylgalactosamine 68 Phase 2a Trial 68 Pralatrexate 68 octreotide implant 68 TOCOSOL Camptothecin 68 Refractory Hodgkin Lymphoma 68 Teriflunomide 68 Receives Orphan Drug 68 Adjuvant Treatment 68 oral dual endothelin 68 CTA# Injection 68 Annamycin 68 markets Testim ® 68 Tarvacin Anti Cancer 68 SAR# [004] 68 indolent follicular non 68 Intravitreal injections 68 solanezumab 68 PROSTVAC VF 68 delta gamma agonist 68 Æterna Zentaris Inc. 68 Merck Serono Nycomed 68 tumors GIST 68 PSMA ADC 68 DURIN TM 68 NEBIDO VANTAS SUPPRELIN LA 68 Ocrelizumab 68 norepinephrine reuptake inhibitor 68 treatment naïve genotype 68 TLK# 68 Anthracycline 68 TRANSDUR ™ 68 Brentuximab Vedotin SGN 68 MT# MEDI 68 cell lymphoma CTCL 68 GRNOPC1 contains 68 Initiates Dosing 68 Deferiprone 68 IMiDs ® compound 68 sorafenib tablets 68 nasal calcitonin product 67 ATPace TM 67 dyslipidemia hypertension diabetes 67 hepatitis C HCV 67 selective orally bioavailable 67 neuropathic pain spasticity 67 overactive bladder VANTAS R 67 Parathyroid Hormone 67 negative allosteric modulator 67 Glufosfamide 67 highly selective endothelin 67 Motesanib 67 metastatic castration resistant 67 cathepsin K inhibitor 67 Inc. AMEX YMI 67 HQK 67 IMiD 67 immunotherapeutic approaches 67 PF # [002] 67 PEGINTRON TM 67 Kinase Inhibitor 67 palonosetron hydrochloride Injection Dacogen 67 tolevamer 67 UPLYSO 67 inhaled formulation 67 infectious diseases autoimmune diseases 67 ELADUR TM 67 R rilonacept Injection 67 alfa 2a 67 Lupus Nephritis 67 CEQ# 67 Excellarate TM 67 Nanobody 67 Hedgehog Pathway Inhibitor 67 CYP#A# substrate 67 include Healive 67 Disease IBD 67 DIRECT Trial 67 novel synthetic PEGylated 67 Serostim ® 67 investigational pharmacologically unique 67 XP# XP# 67 Telatinib 67 RAS MAPK pathway 67 Receives Approvable Letter 67 Randomized Double blind 67 Sciences ABthrax Albuferon 67 oral JAK#/JAK# inhibitor 67 Submits NDA 67 thalidomide Thalomid 67 DGAT1 inhibitors 67 Phase III Clinical Trial 67 octreotide acetate 67 chimeric monoclonal antibody 67 RNAi therapeutic targeting 67 iloprost synthetic compound 67 CYC# 67 UCB www.ucb group.com 67 TO AVOID PREGNANCY WHILE 67 IMiDs 67 PEG SN# 67 Aptivus ® 67 investigational immunotherapy 67 monoclonal antibody MAb 67 POSIDUR TM ELADUR TM 67 Copegus ® 67 Phase III Trials 67 Panzem NCD 67 initiated Phase Ib 67 commercializing oxidized glutathione 67 dose intramuscular 67 approved incretin mimetic 67 proprietary BiTE ® 67 multicenter Phase II 67 Copegus R 67 addressing idiopathic pulmonary 67 DURECT proprietary 67 Vicinium TM 67 Cutaneous T 67 Gel repository corticotropin injection 67 Opterone R 67 initiated Phase 1b 67 Gleevec resistant 67 cyclin dependent kinase inhibitor 67 Mycophenolate Mofetil 67 gets USFDA nod 67 ABL inhibitor 67 Zolinza 67 highly selective inhibitor 67 6R BH4 67 Prolongs Survival 67 investigational oral hepatitis C 67 ADAGEN 67 Treatment Naïve 67 class anticancer quinolone 67 pan BCR ABL 67 CRM# Protein 67 BioSante Pharmaceuticals Announces 67 mitogen activated ERK kinase 67 XL# XL# XL# XL# 67 ABLYNX 67 TÎ ² 4 67 topical anti infective 67 Oracea TM 67 selective A2A adenosine receptor 67 HuLuc# 67 5 FU capecitabine 67 successfully commercialize Iluvien 67 aerosolized AAT 67 hormone LHRH antagonist 67 Auxilium transmucosal film 67 multiple sclerosis psoriasis 67 gastrointestinal stromal 67 Aztreonam lysine 67 world safest multivalent 67 rheumatoid arthritis thrombocytopenia 67 novel topoisomerase 67 Allovectin 7 R 67 Phase III Clinical Trials 67 urocortin 2 67 evaluating mipomersen 67 nilotinib Tasigna 67 Radezolid 67 Earns Milestone Payment 67 Inhalation Aerosol 67 FDA Accepts 67 Xeloda ® 67 R bendamustine hydrochloride 67 Gonal f R 67 EGFr humanized monoclonal antibody 67 pegylated interferon alfa 2a 67 Canvaxin TM 67 drug ISA# 67 KL4 Surfactant 67 Shows Statistically Significant 67 galiximab 67 Seliciclib CYC# 67 ACTIQ ® 67 selective angiogenic kinase inhibitor 67 rasagiline tablets 67 JAK1 67 Namenda ® 67 Tykerb lapatinib 67 compound KOS 67 HCV protease inhibitors 67 Phase lll 67 HDAC Inhibitor 67 gastrointestinal mucositis 67 small molecule thrombopoietin 67 Tyrosine Kinase Inhibitor 67 ARRY # 67 cosmetic cosmeceutical products 67 anti amnesic 67 ALK inhibitor 67 Angiocept 67 Therapeutic Competitors companiesandmarkets.com adEgemonye 67 Pivotal Trial 67 PrevOnco 67 taxane resistant 67 signal detection CTSD 67 Febuxostat 67 inhibit oxidative stress 67 Phase Ib clinical trials 67 generation DACH Platinum 67 rALLy 67 PRT# 67 Solazed 67 markets COLAZAL 67 antibiotic candidate Ramoplanin 67 Traficet EN 67 cancer indications bafetinib 67 Genentech Rituxan 67 Thiarabine 67 NEBIDO R 67 ATC ovarian cancer 67 allosteric modulator NAM 67 lumiliximab 67 Phase Ib II 67 VitiGam 67 Bilive R combined 67 biased ligand 67 5 HT6 67 ZOLINZA 67 targeting miR 67 Roche Boniva 67 cancer immunotherapies 67 rheumatoid arthritis inflammatory bowel 67 Therapeutic Vaccine 67 Study Evaluating 67 vascular occlusive diseases 67 Homspera TM 67 immunosuppressive compound 67 GTC recombinant human 67 FUSILEV enhances 67 refractory metastatic 67 Ceflatonin 67 Diabetic Macular Edema 67 complement inhibitor eculizumab 67 lucinactant 67 GlycoPEGylated hemostasis compounds 67 Quinamed 67 selective antagonist 67 Wafer polifeprosan 67 Dacogen injection 67 Nitazoxanide 67 cardio renal 67 ONCONASE R 67 Acute Attacks 67 Stimulon adjuvant 67 Nasdaq XTLB 67 class mGluR5 inhibitor 67 ® decitabine 67 hypertension osteoarthritis 67 cortisol synthesis 67 SIRT1 activators 67 registrational Phase 67 Intravenous Human 67 IV Busulfex 67 Cyclooxygenase Inhibiting Nitric Oxide 67 corticosteroid dexamethasone 67 Levoleucovorin 67 vemurafenib 67 Warner Chilcott Actonel 67 ILUVIEN ® 67 HuMax TAC 67 semi synthetic lipoglycopeptide 67 ® lenalidomide 67 Announces Tentative Approval 67 Diamyd r 67 davalintide 67 dextromethorphan quinidine 67 Vaccine Protects Against 67 immunotherapeutic agent 67 MSCRAMM ® 67 CD# monoclonal antibody 67 Cardium Therapeutics TM 67 hoFH 67 G#DT 67 HYVISC ® treatment 67 Anturol TM 67 RAF kinase 67 Intravenous CP 67 Augment TM 67 Degarelix 67 novel histone deacetylase 67 cetuximab Erbitux 67 Prochymal TM 67 Receive Milestone Payment